Allogene Therapeutics, Inc.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on management’s current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In some cases, forward-looking statements may be identified by words such as “expect,” “believe,” “plan,” “intend,” “estimate,” “target,” “potential,” “could,” “will,” “anticipate,” “support,” “designed to,” “continue,” “project,” and similar expressions. Forward-looking statements in this press release include, but are not limited to, statements regarding the timing, design, conduct, and results of Allogene’s clinical trials and analyses, including the anticipated mid-2027 clinical update and expected completion of enrollment by year-end 2027 in the ALPHA3 trial, and the planned presentation of updated Phase 1 RESOLUTION trial data for ALLO-329 at ACR in November 2026; the extent to which expansion of the ALPHA3 trial network, MRD screening, investigator engagement and enrollment in Asia-Pacific and community oncology practices may support trial enrollment and future patient access; the rate and pace of enrollment and dose escalation in the RESOLUTION trial, and the selection of a potential Phase 2 dose and conditioning regimen; the timing, scope and anticipated findings of planned scientific presentations and investor events, including at ACR, ASH and SITC; the potential clinical benefits, safety, tolerability, durability, and efficacy of Allogene’s product candidates; the potential for MRD-guided first-line consolidation to improve outcomes in LBCL; the potential for MRD screening and outpatient administration to facilitate earlier intervention and treatment in community care settings; the potential value and advantages of allogeneic CAR T, including its ability to address clinical and practical barriers presented by other therapies; the potential to deliver allogeneic CAR T therapy in outpatient and community care settings and to expand patient access; preparations for possible commercialization of cema-cel, including payer coverage, reimbursement, evidence generation and treatment-site readiness; the potential to reduce or eliminate conventional chemotherapy-based lymphodepletion, and the effects of different ALLO-329 dose levels and conditioning approaches on safety, tolerability and clinical activity, including in systemic sclerosis; the potential utility of Dagger® technology, including the DLL3/CD70 dual CAR T approach, and the translation of preclinical findings into clinical benefit; expectations regarding clinical trial execution and operational performance; and expectations regarding Allogene’s financial position, cash runway, and 2026 operating outlook. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, but not limited to, risks and uncertainties inherent in clinical development (including that interim or early data may not be predictive of later or final results or clinical outcomes), patient enrollment and trial execution risks, including delays in enrollment, data collection and presentation timelines, uncertainties related to MRD testing and its clinical significance and whether MRD-guided treatment will translate into clinically meaningful benefit, the occurrence of adverse safety events, uncertainty regarding the benefits and risks of different lymphodepletion regimens, the possibility that preclinical findings will not translate to clinical results, regulatory risks and uncertainties, manufacturing and CMC risks, reliance on third parties and licensors, commercialization and reimbursement uncertainties, competitive developments, intellectual property and contractual risks, and financial risks, including the need for additional capital. These and other risks and uncertainties are described more fully in Allogene’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, being filed with the SEC today. All forward-looking statements in this press release speak only as of the date of this press release, and Allogene undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Dagger® is a trademark of Allogene Therapeutics, Inc.

Allogene’s investigational AlloCAR T oncology products utilize Cellectis technologies. Cemacabtagene ansegedleucel (cema-cel) was developed based on an exclusive license granted by Cellectis to Servier. Servier has granted Allogene exclusive rights to cema-cel in the U.S., all EU Member States and the United Kingdom. The anti-CD70 AlloCAR T program is licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to this AlloCAR T program. ALLO-329 (CD19/CD70) in autoimmune disease uses CRISPR gene-editing technology.